Analysis of bacteremia/fungemia and pneumonia accompanying acute myelogenous leukemia from 1987 to 2001 in the Japan Adult Leukemia Study Group

[1]  W. Jędrzejczak,et al.  Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[2]  T. Naoe,et al.  Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study , 2010, International journal of hematology.

[3]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  K. Mitani,et al.  A randomized, postremission comparison of four courses of standard‐dose consolidation therapy without maintenance therapy versus three courses of standard‐dose consolidation with maintenance therapy in adults with acute myeloid leukemia , 2005, Cancer.

[5]  L. Leibovici,et al.  Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients , 2005, Annals of Internal Medicine.

[6]  R. Ohno,et al.  Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Tanimoto,et al.  Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Donnelly,et al.  Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. , 2004, The Lancet. Infectious diseases.

[9]  B. Djulbegovic,et al.  Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Taguchi,et al.  Management of infectious complications in patients with acute leukemia during chemotherapy : A questionnaire analysis by the Japan Adult Leukemia Study Group , 2003 .

[11]  R. Wenzel,et al.  Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[13]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[14]  Y. Tanaka,et al.  Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  E. Rubenstein,et al.  Textbook of febrile neutropenia , 2001 .

[16]  S J Lin,et al.  Aspergillosis case-fatality rate: systematic review of the literature. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  J. Armitage,et al.  2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Y. Kanda,et al.  Prophylactic action of oral fluconazole against fungal infection in neutropenic patients , 2000, Cancer.

[19]  William R. Kirkpatrick,et al.  Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes , 2000, Medicine.

[20]  T. Naoe,et al.  Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991. , 1999, International journal of hematology.

[21]  M. Tanimoto,et al.  No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group. , 1999, International journal of hematology.

[22]  T. Masaoka.  Management of fever of unknown origin in the neutropenic patient: the Japanese experience. , 1998, International journal of hematology.

[23]  A. Glasmacher,et al.  Pulmonary infiltrates in neutropenic patients with acute leukemia during chemotherapy: outcome and prognostic factors. , 1998, Chest.

[24]  L. Young,et al.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  S. Kohno,et al.  Plasma (1→3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes , 1995, The Lancet.

[26]  W. Hiddemann,et al.  Interventional antimicrobial therapy in febrile neutropenic patients , 1994, Annals of Hematology.

[27]  W. Hiddemann,et al.  Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study , 1994, Cancer.

[28]  T. Naoe,et al.  Randomized study of individualized induction therapy with or without vincristine, and of maintenance—intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML‐87 study of the Japan adult leukemia study group , 1993 .

[29]  Masahiko Watanabe,et al.  Granulocyte colony‐stimulating factor (G‐CSF) receptors on acute myeloblasts leukaemia cells and their relationship with the proliferative response to G‐CSF in clonogenic assay , 1991, British journal of haematology.

[30]  L. Young,et al.  From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. , 1990, The Journal of infectious diseases.

[31]  A. Bernard,et al.  Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  T. Naoe,et al.  Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M. Tomonaga,et al.  Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG). , 1992, Leukemia.

[34]  L. Young,et al.  GUIDELINES FROM THE INFECTIOUS DISEASES SOCIETY OF AMERICA 1997 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever , 1997 .